Reviewed by the PeptideMind Team ยท Updated August 5, 2026
Mito Prime Blend (NAD+/MOTS-c/5-Amino-1MQ) Dosage Guide, Benefits & Side Effects
Mito Prime Blend (MitoPrime) pairs NAD+, MOTS-c & 5-Amino-1MQ in a 10:1:1 ratio. Get the dosage guide, reconstitution tips, benefits, and side effects.
As seen on
Mito Prime Blend Dosage Schedule
A fixed-ratio daily blend of NAD+, MOTS-c, and 5-Amino-1MQ designed to support cellular energy production and metabolic research. The three peptides are combined and cannot be dosed separately.
Six Week Cellular Energy Blend Protocol
6 weeks, focused on metabolic health.
Daily dosing
Taken daily.
11 mg per injection
11 mg per injection, given just under the skin in the abdomen or thigh.
This blend combines NAD+, MOTS-c, and 5-Amino-1MQ in a fixed 10:1:1 ratio to support cellular energy and metabolic research. Because the components are mixed together, they must be dosed as one combined amount rather than independently.
What is Mito Prime Blend?
Mito Prime is a three-component research blend that packs NAD+ (100 mg), MOTS-c (10 mg), and 5-Amino-1MQ (10 mg) into a single 120 mg lyophilized vial in a 10:1:1 ratio. This exact composition is independently confirmed across multiple research-chemical vendors, commonly sold at ~99% purity with HPLC/LC-MS COAs. Each ingredient targets cellular energy, metabolism, and the biology of aging from a different angle. Only MOTS-c is a true peptide; NAD+ is a coenzyme and 5-Amino-1MQ is a small-molecule NNMT inhibitor, though all three are commonly marketed together as a 'peptide blend.' No human or animal trial has tested this exact three-compound combination; the rationale and evidence below are inherited from the individual components, most of which is preclinical rodent data.
METABOLIC
Mtp
Longevity
Our top-rated vendor
Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing, no paid placements, no affiliate influence. We update this list as new data comes in.
Based on current scores, this vendor ranks highest across those criteria.
Frequently Asked Questions About Mito Prime Blend
Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.
Mito Prime Blend Reconstitution Guide
Mito Prime Blend is supplied as a freeze-dried powder that must be mixed into a injectable solution before use.
120 mg lyophilized vial
Mito Prime Blend is supplied as a freeze-dried powder that must be mixed into a injectable solution before use.
3 mL bacteriostatic water
Adding 3 mL of bac water to a 120 mg vial gives a workable concentration for syringe dosing. More water makes microdosing easier; less concentrates each draw.
Storage after mixing
Mito Prime ships as a lyophilized (freeze-dried) powder. Store the unreconstituted vial refrigerated or frozen and protected from light until ready to reconstitute, following standard peptide/coenzyme handling. Once reconstituted with bacteriostatic water, keep refrigerated at 2-8ยฐC; vendor guidance for this specific blend indicates use within roughly 4-6 weeks, and any solution that becomes discolored or cloudy should be discarded. After reconstitution, keep the vial refrigerated and use within 30 days.
Reconstitution steps
Remove caps & sanitize stoppers
Attach needle to syringe
Draw 3 mL bacteriostatic water
Insert needle into Mito Prime Blend vial
Release water gently down the side
Swirl to dissolve โ don't shake
Check for full dissolution
Refrigerate Mito Prime Blend โ good for 30 days
What Are the Benefits of Mito Prime Blend?
What research says it may help with, and how it works in the body.
fat loss
5-Amino-1MQ (~7% body weight, ~35% fat mass reduction over 11 days at 20mg/kg TID SC; Neelakantan et al. 2018) and MOTS-c (obesity prevention over 5 weeks at 15mg/kg/day IP; Lee et al. 2015) both reduced fat mass in diet-induced-obese mice through NAD+-linked and AMPK-linked mechanisms. Human confirmation is missing for both.
energy and metabolism
NAD+ is required for ATP production, and topping up a declining pool is the mechanistic rationale for this blend (Covarrubias et al. 2020/21); a controlled human infusion study confirmed plasma NAD+ rises with infusion but did not measure subjective energy outcomes.
metabolic health
MOTS-c activated AMPK and improved insulin sensitivity in diet-induced obese mice by week 4 of daily dosing, and reduced age-related insulin resistance in older animals (Lee et al. 2015, Cell Metabolism).
longevity
The most speculative indication, resting on NAD+ decline as a driver of aging (Covarrubias et al. 2020/21) and on MOTS-c improving physical performance and healthspan markers in aged mice, including animals started late in life (Reynolds et al. 2021, Nature Communications). No human longevity outcome exists for any of these compounds alone or blended.
What Are the Side Effects of Mito Prime Blend?
Who should avoid it, warning signs to watch for, and what to know before combining it with other compounds.
Who Should Avoid It
Avoid if pregnant, nursing, or managing a hormone-sensitive condition
Known hypersensitivity to NAD+, MOTS-c, or 5-Amino-1MQ
Active cardiovascular disease (per-component NAD+ infusion data includes cardiac symptoms)
Not established for use in minors
Stop Right Away If You Notice
Severe flushing, chest tightness, or difficulty breathing during or after dosing
Persistent or severe gastrointestinal upset, vomiting, or dehydration
Signs of allergic reaction: rash, hives, swelling, or difficulty breathing
Spreading redness, warmth, or discharge at the injection site
Unusual heart palpitations or chest pain
Persistent severe headache or dizziness
Milder Signs to Watch For
Compare the Peptides in Mito Prime Blend
See how 5-Amino-1MQ, MOTS-c, NAD+ stack up individually on dosing, mechanism, and research before you combine them in Mito Prime Blend.
Overview
- Type
- Single peptide
- Primary category
- Metabolic
- Secondary categories
- WeightLongevity
- Research status
- Preclinical
- FDA approved
- Not FDA approved
- Popularity
- 8/10
- Body targets
- Metabolic
- Price range
- Human trial status
- Animal studies only
- Legal status
- Research chemical
- WADA status
- Not banned
Dosing
- Dose
- 1โ5 mg
- Frequency
- Daily
- Cycle
- 16+ weeks
- Route of administration
- Oral
- Common vial sizes
- 10mg50mg
Research
- Molecular weight
- 159.21 g/mol
- Half-life
- โ
- Median onset
- โ
- Prescription alternative
- Has alternative
- Receptor target
- โ
- Receptor action
- Modulator
- Mechanistic pathways
- NNMT NAD Metabolism
Included in
Overview
- Type
- Single peptide
- Primary category
- Metabolic
- Secondary categories
- Longevity
- Research status
- Phase 1
- FDA approved
- Not FDA approved
- Popularity
- 9/10
- Body targets
- MetabolicMuscle
- Price range
- Human trial status
- Anecdotal human reports
- Legal status
- Research chemical
- WADA status
- Banned
Dosing
- Dose
- 2.5โ5 mg
- Frequency
- 2ร/week
- Cycle
- 8-12 weeks
- Route of administration
- Subcutaneous
- Common vial sizes
- 10mg20mg+1
Research
- Molecular weight
- 2174.59 g/mol
- Half-life
- 2 hrs
- Median onset
- โ
- Prescription alternative
- No alternative
- Receptor target
- โ
- Receptor action
- Unknown
- Mechanistic pathways
- Mitochondrial Metabolic Regulation
Included in
Overview
- Type
- Single peptide
- Primary category
- Longevity
- Secondary categories
- Metabolic
- Research status
- Experimental
- FDA approved
- Not FDA approved
- Popularity
- 7/10
- Body targets
- MetabolicMuscle
- Price range
- Human trial status
- Human RCTs
- Legal status
- Research chemical
- WADA status
- Not banned
Dosing
- Dose
- 20โ100 mg (titrated)
- Frequency
- 2โ3ร/week
- Cycle
- Ongoing
- Route of administration
- Subcutaneous
- Common vial sizes
- 100mg250mg+3
Research
- Molecular weight
- 663.43 g/mol
- Half-life
- โ
- Median onset
- โ
- Prescription alternative
- No alternative
- Receptor target
- โ
- Receptor action
- Modulator
- Mechanistic pathways
- NAD Sirtuin MetabolismNeuropeptide Cognitive
Included in
Is Mito Prime Blend FDA approved?
Mito Prime Blend is not an FDA-approved drug. It is intended for research purposes only and is not approved for human consumption, diagnostic, or therapeutic use.
Research Use Only
Mito Prime Blend has not been evaluated by the FDA for safety or efficacy in humans.
No Clinical Oversight
Not manufactured under FDA-regulated quality or clinical standards.
Unregulated Sourcing
Purity, dosing, and sourcing are not verified through FDA testing or oversight.
Mito Prime Blend Cycle Length: How Long Should It Last?
This breaks down how long a typical Mito Prime Blend cycle runs and what research suggests happens at each stage. Research shows that staying on a peptide continuously, without a break, may make it less effective over time.
That's why most research protocols build in a break between cycles, often called a washout period, to let the body reset before starting again.
- Day 1-3
- Acute AMPK activation and transient plasma NAD+ rise. Reasoned estimate combining MOTS-c's rapid AMPK-phosphorylation window (Lee et al. 2015, Cell Metabolism) with NAD+ infusion pharmacokinetics showing plasma peaks within hours of dosing.
- Week 1-2
- Early fat-mass reduction and exercise-capacity gains observed in rodents: ~7% body weight and ~35% fat-mass loss after 11 days of 5-Amino-1MQ dosing in obese mice (Neelakantan et al. 2018); doubled running capacity after 2 weeks of daily MOTS-c dosing in aged mice (Reynolds et al. 2021).
- Week 4-5
- Peak insulin-sensitization and metabolic homeostasis effects, based on the MOTS-c diet-induced-obesity mouse study, which showed insulin-sensitivity gains by week 4 and sustained improvement through 5 weeks of daily dosing (Lee et al. 2015).
- Month 2-4
- Reasoned estimate, not blend-specific: sustained cellular-energy/NAD+ pathway effects with continued dosing, extrapolated from chronic nicotinamide riboside rodent studies run 9-18 weeks, which showed dose-dependent and inconsistent metabolic benefit rather than a clear peak.
- Post-Discontinuation
- Reasoned estimate: plasma/tissue NAD+ elevation and AMPK signaling likely return toward baseline within 1-2 weeks of stopping, based on NAD+ pharmacokinetics showing rapid reversal within 24-48 hours after single-dose infusion. No direct discontinuation/washout data exists for MOTS-c or 5-Amino-1MQ.
Mito Prime Blend Research References
It is a preclinical compound
Mito Prime Blend
Mito Prime Blend is a preclinical compound
Covarrubias AJ, Perrone R, Grozio A, Verdin E. Nature Reviews Molecular Cell Biology, Vol 22, pp. 119-141 (published online 22 Dec 2020; print issue 2021). Describes a gradual drop in tissue and cellular NAD+ across aging in rodents and humans, linked to metabolic disease, cognitive decline, and sarcopenia. PMID 33353981.
2021
Lee C, Zeng J, Drew BG, et al. Cell Metabolism 21(3):443-454. Original paper showing MOTS-c activates AMPK, improves insulin sensitivity in diet-induced obese mice (15mg/kg/day IP over 5 weeks), and reduces age-related insulin resistance in older animals.
2015
Reynolds JC, Bwiza CP, Lee C, et al. Nature Communications 12:470. Showed MOTS-c is induced by exercise (~11.9-fold rise in skeletal muscle) and that treating mice, including those started late in life (22 months), boosted running capacity and physical performance across young, middle-aged, and old groups.
2021
Kraus D, Yang Q, Kong D, et al. Nature 508:258-262. Antisense-oligonucleotide knockdown of NNMT in fat and liver protected mice against diet-induced obesity, glucose intolerance, and fatty liver, partly by shifting adipose NAD+ and SAM levels. This paper established NNMT as a target; it did not test the small-molecule 5-Amino-1MQ itself.
2014
Neelakantan H, Vance V, Wetzel MD, et al. Biochemical Pharmacology 147:141-152. This is the paper that actually tested 5-Amino-1MQ: diet-induced-obese mice given 5-Amino-1MQ (20mg/kg TID SC for 11 days) showed ~7% body-weight loss and ~35% fat-mass reduction without changed food intake.
2018
Awosemo O, Neelakantan H, Watowich S, et al. Journal of Pharmaceutical and Biomedical Analysis. Reported rat half-life of ~3.8h (IV) / ~6.9h (oral) and ~38.4% oral bioavailability for 5-Amino-1MQ. No human PK data exists for this compound.
2021